| Name | liraglutide |
|---|---|
| Synonyms | liraglutide |
| Description | Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus. |
|---|---|
| Related Catalog | |
| Target |
GLP-1 receptor[1] |
| In Vitro | Liraglutide binds to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Liraglutide is an injectable drug for the treatment of type 2 diabetes, also can be used to treat obesity in adults with some related comorbidity. Liraglutide activated AMPK/SREBP1 pathway in oxLDL-stimulated Raw264.7 cells[1]. |
| Cell Assay | Raw264.7 macrophage cells are cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum in a humidified 37°C incubator with 5% CO2. The cells are incubated with oxLDL (50 μg/mL), Liraglutide (0.1, 0.5, 1 and 2 nM) or Exendin-3 (9-39) (1, 10 and 100 nM) alone, or in combination[1]. |
| References |
| Molecular Formula | C172H265N43O51 |
|---|---|
| Molecular Weight | 3751.20000 |
| Exact Mass | 3748.95000 |
| PSA | 1513.76000 |
| LogP | 6.12960 |
| Storage condition | -20°C |